Skip to main content
Caplight Logo









Neiges Biotechnologies

Neiges Biotechnologies

Private
MontrealHealthcare & Life Scienceshttps://www.neigesbiotech.com/

Last Round

Grant

Jun 22, 2026

Total Funding Raised

$10,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neiges Biotechnologies is a biotechnology company that develops human-derived organoid models of intestinal tissues to advance preclinical research and drug discovery for gastrointestinal therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

organoidpreclinical researchdrug discoverynew approach methodologiesNAMintestinal organoidanimal-free testingin vitro modelsgastrointestinal therapeuticsdisease modelingorgan-on-a-chiptranslational researchbiotech startuphigh-throughput screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neiges Biotechnologies Comparables

Compare Neiges Biotechnologies with similar companies based on industry and business-model similarity.

Neiges Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Intero Biosystems
93%
Altis Biosystems
83%
Vivodyne
79%

Neiges Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 22, 2026

Neiges Biotechnologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Received grant funding from Consortium Québécois and Gouvernement du Québec.

Neiges Biotechnologies Filings

Explore SEC and related filing metadata, where available.

Neiges Biotechnologies filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neiges Biotechnologies's valuation, stock price, and market status.

Is Neiges Biotechnologies a public or private company?

Neiges Biotechnologies is a private company.

What is the current stock price of Neiges Biotechnologies?

Neiges Biotechnologies is a private company with no public stock price. Caplight tracks Neiges Biotechnologies's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Neiges Biotechnologies worth (valuation)?

Valuation information for Neiges Biotechnologies is not publicly available.

Can I buy Neiges Biotechnologies stock?

Neiges Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neiges Biotechnologies's last funding round?

Neiges Biotechnologies's most recent funding round was Grant on June 22, 2026.

Who are the main investors in Neiges Biotechnologies?

Key investors in Neiges Biotechnologies include Consortium Québécois sur la découverte du médicament, District 3 Innovation Center, Gouvernement du Québec, Front Row Ventures.

Will Neiges Biotechnologies IPO soon?

No public IPO plans have been announced for Neiges Biotechnologies.

How can I track Neiges Biotechnologies secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neiges Biotechnologies's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontreal
Year FoundedN/A
Last FundingJun 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?